A diabetic patient with peripheral arterial disease
Authors:
Tomáš Petrovič; Peter Jackuliak; Juraj Payer
Authors‘ workplace:
V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in:
Forum Diab 2018; 7(1): 34-39
Category:
Overview
Diabetes mellitus and peripheral arterial disease frequently occur particularly at older age. Their simultaneous course presents a significant risk of vascular complications. The authors deal with a mutual relationship of the two diseases, the incidence of complications and ongoing pathophysiological changes as well as diagnostic possibilities. The treatment places emphasis primarily on influencing the risk factors of both diseases – ban on smoking, normalization of blood pressure, the lipid spectrum values, a rigorous control of blood glucose. The specific treatment for the peripheral arterial disease is always based on movement therapy, as to medication antiplatelet drugs are indicated for symptomatic patients, as to vasoactive drugs prostanoids or possibly cilostazol or naftidrofuryl are administered to a selected group of patients. Revascularization is justified in patients with life-limiting claudications with an insufficient response to conservative treatment.
Key words:
diabetes mellitus, diagnostics PAD, pathogenesis PAD, peripheral arterial disease (PAD), treatment PAD
Received:
28. 2. 2018
Accepted:
7. 3. 2018
Sources
1. Diabetes mellitus. [WHO]. Dostupné z WWW: <http://www.who.int/mediacentre/factsheets/fs138/en/>.
2. Statistics About Diabetes. [American Diabetes Association]. Dostupné z WWW: <http://www.diabetes.org/diabetes-basics/statistics/>.
3. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116(9): 1509–1526. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.116.303849>. Erratum in Correction. [Circ Res. 2015].
4. Stvrtinová V, Sefránek V, Murín J et al. Peripheral arterial disease of extremities – guidelines for diagnostic and treatment. Vnitr Lek 2008; 54(2): 195–202.
5. Armstrong EJ, Rutledge JC, Rogers JH. Coronary artery revascularization in patients with diabetes mellitus. Circulation. 2013;128(15): 1675–1685. Dostupné z DOI <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002114>.
6. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47(5): 921–929. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2005.09.065>.
7. Forbang NI, McDermott MM, Liao Y et al. Associations of diabetes mellitus and other cardiovascular disease risk factors with decline in the ankle-brachial index. Vasc Med 2014; 19(6): 465–472. Dostupné z DOI: <http://dx.doi.org/10.1177/1358863X14554033>.
8. Fowkes FG, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329–1340. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(13)61249–0>.
9. Faglia E, Caravaggi C, Marchetti R, et al. Screening for peripheral arterial disease by means of the ankle-brachial index in newly diagnosed Type 2 diabetic patients. Diabet Med 2005; 22(10): 1310–1314. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2005.01612.x>.
10. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008; 51(5): 747–755. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–008–0940–0>.
11. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes--a review. Diabet Med 2010; 27(1): 4–14. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2009.02866.x>.
12. Dick F, Diehm N, Galimanis A et al. Surgical or endovascular revascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45(4): 751–761. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jvs.2006.12.022>.
13. Grenon SM, Vittinghoff E, Owens CD et al. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: Insights from the Heart and Soul Study. Vasc Med 2013; 18(4): 176–184. Dostupné z DOI: <http://dx.doi.org/10.1177/1358863X13493825>.
14. Aiello A, Anichini R, Brocco E et al. Treatment of peripheral arterial disease in diabetes: a consensus of the Italian Societies of Diabetes (SID, AMD), Radiology (SIRM) and Vascular Endovascular Surgery (SICVE). Nutr Metab Cardiovasc Dis 2014; 24(4): 355–369. Dostupné z DOI: <http://dx.doi.org/10.1016/j.numecd.2013.12.007>.
15. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141(6): 421–431.
16. Paneni F, Beckman JA, Creager MA et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34(31): 2436–2443. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht149>.
17. Aboyans V, Criqui MH, Abraham P,et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126(24): 2890–2909.
18. Park SC, Choi CY, Ha YI et al. Utility of Toe-brachial Index for Diagnosis of Peripheral Artery Disease. Arch Plast Surg 2012; 39(3): 227–231. Dostupné z DOI: <http://dx.doi.org/10.5999/aps.2012.39.3.227>.
19. Hoyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 2013; 58(1): 231–238. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jvs.2013.03.044>.
20. Gerhard-Herman MD, Gornik HL, Barrett C et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135(12): e726-e779. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000471>. Erratum in Correction to: 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. [Circulation. 2017].
21. Aboyans V, Ricco JB, Bartelink M-L EL et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2017; 39(9): 720–729. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx095>.
22. Met R, Bipat S, Legemate DA et al. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA 2009; 301(4): 415–424. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.301.4.415>.
23. Singh S, Armstrong EJ, Sherif W et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med 2014;19(4):307–314. Dostupné z DOI: <http://dx.doi.org/10.1177/1358863X14538330>.
24. Lane R, Ellis B, Watson L et al. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014; (7): CD000990. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD000990.pub3>.
25. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev 2010; 1: CD006544. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD006544.pub2>. Update in Prostanoids for critical limb ischaemia. [Cochrane Database Syst Rev 2018].
26. Piaggesi A, Vallini V, Iacopi E et al. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol 2011; 59(1): 101–108.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2018 Issue 1
Most read in this issue
- PCSK9 inhibitors and the role of evolocumab in the therapy for patients with hyperlipoproteinemia
- Vildagliptin: experience and prospects
- A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)
- Comprehensive approach in the management of patients with diabesity